Rapidscan Pharma Solutions

Rapidscan Pharma Solutions is a pharmaceutical company specializing in the development and commercialization of pharmacological stress agents for cardiac diagnostic imaging. The company's flagship product is Rapiscan (regadenoson), a selective adenosine A2A receptor agonist used to induce vasodilation during radionuclide myocardial perfusion imaging in patients unable to perform adequate exercise stress tests. Rapidscan Pharma Solutions holds the marketing authorization for regadenoson in the European Union, the United Kingdom, and several other international territories. The company maintains a strategic partnership with GE Healthcare for the distribution and promotion of Rapiscan. Its focus remains on improving the diagnosis of coronary artery disease through specialized cardiovascular agents.